Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: Risk analysis in hepatitis B surface antigen-negative cases

Journal of Rheumatology

Volumn 38, Issue 10, 2011, Pages 2209-2214

  Kato, Masaru ^a   Atsumi, Tatsuya ^a   Kurita, Takashi ^a   Odani, Toshio ^a   Fujieda, Yuichiro ^a   Otomo, Kotaro ^a   Horita, Tetsuya ^a   Yasuda, Shinsuke ^a   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoimmune diseases; Hepatitis B virus; Immunosuppression

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INFLIXIMAB; METHOTREXATE; NUCLEOSIDE ANALOG; PREDNISOLONE; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTEREMIA; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERSTITIAL PNEUMONIA; LYMPHOPROLIFERATIVE DISEASE; MALE; MICROSCOPIC POLYANGIITIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS REACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; DNA, VIRAL; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RISK ASSESSMENT; VIRUS ACTIVATION;

EID: 80053483118     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110289     Document Type: Article

References (31)

1. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2:528-30.
2. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-9. (Pubitemid 12139868)
3. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-8. (Pubitemid 11123366)
4. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975;68:105-12.
5. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
6. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. (Pubitemid 46374607)
8. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
9. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-9. (Pubitemid 32064857)
10. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68. (Pubitemid 44015749)
11. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993;18:1313-8. (Pubitemid 23348415)
12. Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 1992; 103:1649-56.
13. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994;94:907.
14. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003;37:1172-9. (Pubitemid 36538695)
15. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42:302-8. (Pubitemid 40254242)
16. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005;41:1277-82. (Pubitemid 41532669)
17. Kitano K, Kobayashi H, Hanamura M, Furuta K, Ueno M, Rokuhara A, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 2006;77:255-8. (Pubitemid 44181390)
18. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085-9. (Pubitemid 40975032)
19. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-91. (Pubitemid 41216450)
20. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721-4. (Pubitemid 44027603)
21. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004;83:58-60. (Pubitemid 38088239)
22. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930. (Pubitemid 37022596)
23. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008;47:e52-6.
24. Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin Biol Ther 2011;11:533-44.
25. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9. (Pubitemid 46668261)
26. Montiel PM, Solis JA, Chirinos JA, Casis B, Sanchez F, Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28:718-20.
27. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011;46:556-64.
28. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011;21:16-23.
29. Charpin C, Guis S, Colson P, Borentain P, Mattei JP, Alcaraz P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:R179.
30. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010;69:1352-5.
31. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005;79:616-9. (Pubitemid 40365894)